Almost 13 billion doses of the COVID-19 vaccine have been administered around the world, but fewer than 25% of people in low-income countries have received just one dose. Treatments and diagnostic tests – like vaccines – are crucial in managing the pandemic but are distributed unequally.
Join Flinders researcher in intellectual property and health law Dr James Scheibner in exploring the level of inequity of COVID-19 vaccine and treatment distribution and what's being done to improve how poorer countries recover from the pandemic. How do licencing agreements impact generic vaccine manufacturers and what can Australia do to help reduce the burden on low-income countries?
James is a lecturer in law at Flinders University and a researcher into intellectual property and health law, as well as industrial property law and data protection law. His research interests also extend to bioethics, institutional economics (such as common pool resource theory) and the application of these fields to these areas of law. After completing his undergraduate degree in computing and law at the University of Tasmania, James completed his PhD in the area of intellectual property right. James then headed to Switzerland to undertake a two-year post-doctoral research fellowship at ETH Zurich.
Sturt Rd, Bedford Park
South Australia 5042
South Australia | Northern Territory
Global | Online
CRICOS Provider: 00114A TEQSA Provider ID: PRV12097 TEQSA category: Australian University
Flinders University uses cookies to ensure website functionality, personalisation and a variety of purposes as set out in its website privacy statement. This statement explains cookies and their use by Flinders.
If you consent to the use of our cookies then please click the button below:
If you do not consent to the use of all our cookies then please click the button below. Clicking this button will result in all cookies being rejected except for those that are required for essential functionality on our website.